Core Viewpoint - The company, Shouhui Group, has entered into agreements with Pudong Development Bank and Pudong Bank Wealth Management for fixed income investment products, indicating a strategic move to enhance its investment portfolio [1] Group 1: Investment Agreements - On June 5, 2025, Shouhui Group, through its controlled entity in Shenzhen, signed an agreement with Pudong Development Bank and Pudong Bank Wealth Management to invest in a fixed income product with a principal amount of RMB 5,000,000 [1] - On July 30, 2025, Shouhui Group further committed to the same fixed income product by entering into a new agreement with a principal amount of RMB 45,000,000 [1]

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), has entered into several wealth management agreements with Industrial Bank, totaling a principal amount of RMB 185 million (approximately HKD 201 million) for investment products [1] Group 1 - On March 31, 2025, Lifescience Pharmaceutical entered into its first wealth management agreement with Industrial Bank, with a principal amount of RMB 20 million (approximately HKD 21.74 million) for structured deposits [2] - On May 7, 2025, Lifescience Pharmaceutical signed its second wealth management agreement with Industrial Bank and Xinyin Wealth Management, with a principal amount of RMB 10 million (approximately HKD 10.87 million) for fixed income investment products [2] - On May 7, 2025, Lifescience Pharmaceutical entered into its third wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 7, 2025, Lifescience Pharmaceutical signed its fourth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 29, 2025, Lifescience Pharmaceutical entered into its fifth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 35 million (approximately HKD 38.04 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its sixth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 50 million (approximately HKD 54.35 million) [2] - On June 11, 2025, Lifescience Pharmaceutical entered into its seventh wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its eighth wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 40 million (approximately HKD 43.48 million) [2]